Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Levofloxacin Strategies in AECOPD
NCT02067780Phase 3Completed
- Sponsor
- Université de Monastir
- Start
- May 2017
- Primary completion
- Jan 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of levofloxacin in chronic obstructive pulmonary disease (COPD), sponsored by Université de Monastir. Started May 2017; status: completed.
02
Drugs
levofloxacin
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT02067780.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02067780.